SoftBank Group’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
Other funds holding PACB
AIM
NAMA
SoftBank Group's PACB Position: Q2 2026 in Review
SoftBank Group held its Pacific Biosciences (PACB) position steady in Q2 2026 at 20,451,570 shares worth $34.4M. The position accounts for 0.19% of the portfolio, ranked #17.
SoftBank Group first reported a position in PACB in Q4 2024 and has held it in 7 quarters since. The position peaked at $38.2M in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.
- SoftBank Group held 20,451,570 shares of Pacific Biosciences worth $34.4M as of Q2 2026.
- SoftBank Group left its Pacific Biosciences share count unchanged in Q2 2026.
- Pacific Biosciences made up 0.19% of SoftBank Group's portfolio in Q2 2026, its #17 holding.
- SoftBank Group first reported a position in Pacific Biosciences in Q4 2024 and has held it in 7 quarters since.
- SoftBank Group's Pacific Biosciences position peaked at $38.2M in Q4 2025.
- 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.
Based on SoftBank Group's 13F filing for Q2 2026, filed 14 Aug 2026.